Duodenal-jejunal bypass liner for the management of type 2 diabetes mellitus and obesity. A multicenter randomized controlled trial.

Ann Surg 2022; 275: 440-447.

The liner was used for 12 months in this study that included 170 adults with diabetes. Use of the liner reduced glycated haemoglobin by >20 per cent in 54.6 per cent compared to 55.2 per cent in controls (P=0.85).

Comment: Although the liner did have some positive benefits, it failed to improve glycaemic control.